SELARL PHARMACIE DE LA MADELEINE : revenue, balance sheet and financial ratios

SELARL PHARMACIE DE LA MADELEINE is a French company founded 23 years ago, specialized in the sector Commerce de détail de produits pharmaceutiques en magasin spécialisé. Based in NICE (06000), this company of category PME shows in 2022 a revenue of 5.1 M€. Find below the complete financial statements, solvency ratios, working capital requirements and sector comparison.

Data updated on 2026-05-09

Sources : INPI & INSEE SIRENE - Processing : Ministry of Economy

Financial history - SELARL PHARMACIE DE LA MADELEINE (SIREN 449020916)
Indicator 2025 2024 2023 2022 2021 2020 2019 2018 2017 2017 2016
Revenue N/C N/C N/C 5 061 553 € 4 970 998 € 4 809 288 € 4 514 196 € 4 216 035 € 4 113 295 € 1 397 076 € 4 225 119 €
Net income 215 688 € 118 768 € 156 166 € 186 718 € 254 968 € 279 592 € 255 054 € 286 015 € 140 545 € 74 507 € 161 273 €
EBITDA N/C N/C N/C 282 372 € 351 142 € 355 232 € 365 155 € 414 216 € 246 551 € 111 758 € 366 615 €
Net margin N/C N/C N/C 3.7% 5.1% 5.8% 5.7% 6.8% 3.4% 5.3% 3.8%

Revenue and income statement

In 2025, SELARL PHARMACIE DE LA MADELEINE generates positive net income of 216 k€. Net income represents the final profit after all expenses (operating, financial, exceptional) and corporate tax. Change over 2016-2025: 161 k€ -> 216 k€.

Net income (2025) ?
Net income
Definition
Profit or loss after all expenses, including taxes and exceptional items.
Formula
Current income + Exceptional income - Income tax

215 688 €

Loading income statement...

Chart evolution

Show :

Assets

Loading data...

Liabilities

Loading data...

Solvency and debt ratios

The debt ratio (= Financial debt / Equity x 100) stands at 87%. Debt level is high: negotiating margin with banks is reduced. Financial autonomy (= Equity / Total assets x 100) reaches 46%. This high autonomy means the company finances most of its assets through equity, a sign of strength.

Debt ratio (2025) ?
Debt ratio
Definition
Measures the proportion of debt to equity.
Formula
(Financial debt / Equity) x 100
Interpretation
< 50% : Low
50-100% : Moderate
> 100% : High

87.11%

Financial autonomy (2025) ?
Financial autonomy
Definition
Share of equity in the company's total financing.
Formula
(Equity / Total assets) x 100
Interpretation
> 30% : Good autonomy
20-30% : Average
< 20% : Low

45.975%

Asset age ratio (2025) ?
Asset age ratio
Definition
Measures the degree of wear of tangible assets.
Formula
Accumulated depreciation / Gross fixed assets x 100
Interpretation
< 50% : Recent assets
50-70% : Normal wear
> 70% : Aging assets

34.6%

Solvency indicators evolution
SELARL PHARMACIE DE LA MADELEINE

Sector positioning

Debt ratio
87.11 2025
2023
2024
2025
Q1: 13.7
Med: 49.79
Q3: 129.09
Average +10 pts over 3 years

In 2025, the debt ratio of SELARL PHARMACIE DE LA MA... (87.11) ranks above the median of the sector. This ratio measures the weight of debt relative to equity. A reduction effort could improve financial strength.

Financial autonomy
45.98% 2025
2023
2024
2025
Q1: 33.42%
Med: 53.72%
Q3: 72.08%
Average -11 pts over 3 years

In 2025, the financial autonomy of SELARL PHARMACIE DE LA MA... (46.0%) ranks below the median of the sector. This ratio represents the share of equity in total financing. An improvement would strengthen the competitive position.

Liquidity ratios

The liquidity ratio (= Current assets / Current liabilities) stands at 104.49. Concretely, the company has €2 of liquid assets for every €1 of short-term debt: no cash risk within 12 months.

Liquidity ratio (2025) ?
Liquidity ratio
Definition
Ability to meet short-term debts with current assets.
Formula
Current assets / Current liabilities
Interpretation
> 1.5 : Very good
1-1.5 : Fair
< 1 : Liquidity risk

104.491

Liquidity indicators evolution
SELARL PHARMACIE DE LA MADELEINE

Sector positioning

Liquidity ratio
104.49 2025
2023
2024
2025
Q1: 131.03
Med: 182.25
Q3: 258.64
Watch -6 pts over 3 years

In 2025, the liquidity ratio of SELARL PHARMACIE DE LA MA... (104.49) ranks in the bottom 25% of the sector. This ratio measures the ability to cover short-term debt with current assets. A ratio below 1 may signal potential cash flow tensions.

Working capital requirement (WCR) and payment terms

Working capital requirement (WCR) measures the cash timing gap between customer collections and supplier/inventory payments.

Operating WCR (2025) ?
Operating WCR
Definition
Financing requirement generated by the operating cycle (inventory + receivables - trade payables).
Formula
Inventory + Customer receivables - Trade payables
Interpretation
Negative = cash released
Positive = financing needed

0 €

Customer credit (2025) ?
Customer credit (days)
Definition
Average payment term granted to customers.
Formula
(Customer receivables / Revenue incl. VAT) x 360
Interpretation
< 45j : Good
45-60j : Average
> 60j : Long

0 j

Supplier credit (2025) ?
Supplier credit (days)
Definition
Average payment term obtained from suppliers.
Formula
(Trade payables / Purchases incl. VAT) x 360
Interpretation
The longer the term, the better for cash flow

0 j

Inventory turnover (2025) ?
Inventory turnover (days)
Definition
Average storage duration for goods or materials.
Formula
(Inventory / Cost of goods) x 360
Interpretation
The lower the ratio, the faster the turnover

0 j

WCR and payment terms evolution
SELARL PHARMACIE DE LA MADELEINE

Positioning of SELARL PHARMACIE DE LA MADELEINE in its sector

Comparison with sector Commerce de détail de produits pharmaceutiques en magasin spécialisé

Valuation estimate

Based on 277 transactions of similar company sales in 2025, the value of SELARL PHARMACIE DE LA MADELEINE is estimated at 3 426 229 € (range 2 325 055€ - 5 376 225€). This multiples method compares the actual sale price of similar companies to their financial indicators (Revenue, EBITDA, Net Income). It provides a market-based indicative estimate.

Estimated enterprise value 2025
277 transactions
2325k€ 3426k€ 5376k€
3 426 229 € Range: 2 325 055€ - 5 376 225€
NAF 5 année 2025

Valuation method used

Net Income Multiple
215 688 € × 15.9x = 3 426 230 €
Range: 2 325 056€ - 5 376 226€

Only this financial indicator is available for this company.

Valuation evolution

How is this estimate calculated?

This estimate is based on the analysis of 277 actual transactions of similar company sales (same NAF code) registered with BODACC between 2016 and 2025.

  • EBITDA Multiple: Preferred method for profitable SMEs. EBITDA reflects the ability to generate cash.
  • Revenue Multiple: Used for growing companies or those with low profitability. Reflects commercial potential.
  • Net Income Multiple: Relevant for mature companies with stable results.

This estimate is provided for information purposes only. A precise valuation requires in-depth analysis (assets, liabilities, prospects, market...).

Similar companies (Commerce de détail de produits pharmaceutiques en magasin spécialisé)

Compare SELARL PHARMACIE DE LA MADELEINE with other companies in the same sector:

Frequently asked questions about SELARL PHARMACIE DE LA MADELEINE

What is the revenue of SELARL PHARMACIE DE LA MADELEINE ?

The revenue of SELARL PHARMACIE DE LA MADELEINE in 2022 is 5.1 M€.

Is SELARL PHARMACIE DE LA MADELEINE profitable?

Yes, SELARL PHARMACIE DE LA MADELEINE generated a net profit of 216 k€ in 2025.

Where is the headquarters of SELARL PHARMACIE DE LA MADELEINE ?

The headquarters of SELARL PHARMACIE DE LA MADELEINE is located in NICE (06000), in the department Alpes-Maritimes.

Where to find the tax return of SELARL PHARMACIE DE LA MADELEINE ?

The tax return of SELARL PHARMACIE DE LA MADELEINE is available on this page. Click on a year in the 'Data by year' section to view the account details (assets, liabilities, income statement). Data comes from INPI (National Institute of Industrial Property).

In which sector does SELARL PHARMACIE DE LA MADELEINE operate?

SELARL PHARMACIE DE LA MADELEINE operates in the sector Commerce de détail de produits pharmaceutiques en magasin spécialisé (NAF code 47.73Z). See the 'Sector positioning' section above to compare the company with its competitors.